STADA Arzneimittel (ETR:SAZ) has been assigned a €74.40 ($88.57) target price by equities researchers at Nord/LB in a research report issued on Tuesday, December 26th. The firm presently has a “sell” rating on the stock. Nord/LB’s price objective points to a potential downside of 16.01% from the company’s current price.
SAZ has been the topic of several other research reports. Independent Research set a €76.00 ($90.48) target price on shares of STADA Arzneimittel and gave the company a “sell” rating in a report on Tuesday, August 29th. Warburg Research set a €74.40 ($88.57) target price on shares of STADA Arzneimittel and gave the company a “sell” rating in a report on Tuesday, September 5th. S&P Global set a €74.40 ($88.57) target price on shares of STADA Arzneimittel and gave the company a “sell” rating in a report on Friday, November 10th. Finally, Commerzbank set a €66.25 ($78.87) target price on shares of STADA Arzneimittel and gave the company a “sell” rating in a report on Wednesday, December 20th. Four equities research analysts have rated the stock with a sell rating and two have given a hold rating to the company’s stock. The stock has a consensus rating of “Sell” and an average target price of €74.08 ($88.18).
Shares of STADA Arzneimittel (SAZ) traded down €0.08 ($0.10) during midday trading on Tuesday, hitting €88.58 ($105.45). 37,896 shares of the stock traded hands, compared to its average volume of 55,841. STADA Arzneimittel has a one year low of €46.31 ($55.13) and a one year high of €89.76 ($106.86). The stock has a market cap of $5,520.00 and a PE ratio of 58.28.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/stada-arzneimittel-saz-given-a-74-40-price-target-by-nordlb-analysts-2.html.
STADA Arzneimittel Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.